14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
LIVN vs ICUI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over ICU Medical Inc (ICUI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas ICUI carries 41.4/100 (SELL) at $175.76 (18.2x Forward P/E, 6.7% operating margin).
Composite vs. Pillar Nuance: While ICUI currently prints a higher short-term Unified Composite Score (41.4/100 SELL vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 6.7% operating margin) and revenue trajectory (+9.9% vs. +4.4% YoY).
Defensive Composite Rating Caution: Although LIVN compares more favorably head-to-head, both LIVN (38.5/100 SELL) and ICUI (41.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LIVN vs ICUI. Trailing 12-month operating profitability (LIVN 14.3% vs ICUI 6.7%) and valuation multiples (LIVN 19.5x vs ICUI 18.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $4.5B market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment32.2% of Rev ($703M)
90D Engineering Disclosures0 Published
Investor FAQ LIVN vs ICUI Key Questions & Quantitative Answers
As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over ICU Medical Inc (ICUI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas ICUI carries 41.4/100 (SELL) at $175.76 (18.2x Forward P/E, 6.7% operating margin). Composite vs. Pillar Nuance: While ICUI currently prints a higher short-term Unified Composite Score (41.4/100 SELL vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 6.7% operating margin) and revenue trajectory (+9.9% vs. +4.4% YoY). Defensive Composite Rating Caution: Although LIVN compares more favorably head-to-head, both LIVN (38.5/100 SELL) and ICUI (41.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
LIVN leads the Growth & Scale pillar: LIVN posts +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin), compared with ICUI at +4.4% YoY revenue growth and -46.9% YoY earnings growth on $2.18B TTM revenue (38.9% gross margin, 6.7% operating margin). On trailing 12-month operating scale, LIVN generates $1.51B in USD-normalized revenue versus $2.18B for ICUI. In operating R&D and SG&A reinvestment, LIVN deploys 53.3% of Rev ($803M) (0 90-day corporate R&D disclosures) versus 32.2% of Rev ($703M) (0 disclosures) for ICUI.
ICUI screens cheaper on headline valuation multiples. LIVN trades at 19.5x Forward P/E, 26.5x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin), whereas ICUI trades at 18.2x Forward P/E, 74.7x Trailing P/E, 0.09x PEG, and 2.0x EV/Revenue (15.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LIVN (15.5% ROE) versus ICUI (2.8% ROE) capital efficiency.
In options market volatility and institutional positioning, LIVN carries 36.9% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 67% Vol realized risk). By comparison, ICUI carries 39.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.89β · 40% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.